ClinicalTrials.gg
CompletedNCT02001584Updated Jul 8, 2014

A Study to Examine the, Safety, Tolerability and Pharmacokinetics Co-Administered Baclofen and Memantine in Obese and Lean, Otherwise Healthy Adults

A Phase 1 interventional study of Baclofen and Memantine in Healthy Volunteers; and Obese, Otherwise Healthy Volunteers, sponsored by Gedeon Richter Plc.. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2014-07-08.

Sponsored by Gedeon Richter Plc. · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 453 studies in Obesity with a site in United Kingdom — 93 open to participants now, 127 under way, 40 of them phase 3. Obesity · United Kingdom.

Phase 1
27 of 453
3 open now
Registered
93rd of 453
by date

Among the 453 studies in Obesity with a site in United Kingdom, this one is one of 27 in phase 1, and was the 93rd registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

Browse Obesity studies →

Open to participants now

93 of the 453 studies in Obesity with a site in United Kingdom are open now. Recruiting first, the newest first:

88 more — sign in →

All 93 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 453 studies in Obesity with a site in United Kingdom, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the safety, tolerability and pharmacokinetics of a predefined dose range of co-administered Baclofen and Memantine in non-obese (Part A) and obese (Part B), otherwise healthy subjects.

03

Conditions studied

  • Healthy Volunteers;
  • Obese, Otherwise Healthy Volunteers

Browse trials for

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All

Eligibility criteria

Inclusion Criteria:

  1. Adult males or females aged 18 to 45 years inclusive;
  2. Subjects with :

    For Part A: ≥18 kg/m² and ≤25 kg/m²; For Part B: ≥33 kg/m² and ≤40 kg/m².

  3. Subjects with a total body weight of ≥50 kg (Part A and Part B);
  4. Subjects who are healthy as determined by the Investigator based on pre study medical history, physical examination, vital signs (blood pressure, pulse rate, respiratory rate and body temperature) and 12-lead at screening and each admission;
  5. Subjects whose clinical laboratory test results are not and are acceptable to the Investigator at screening and each admission;
  6. , alanine aminotransferase, alkaline phosphatase and ≤1.5 x (ULN);
  7. Subjects who are negative for surface antigen (HBsAg), antibody and (HIV) I and II tests at screening;
  8. Subjects who are negative for drugs of abuse and alcohol tests at screening and each admission;
  9. Subjects who are non-smokers or who have not smoked or used nicotine-containing products for at least 3 months prior to screening;
  10. Subjects with an estimated ≥100 mL/minute for male subjects or

    ≥90 mL/minute for female subjects (Cockcroft-Gault method) at screening;

  11. Subjects who are able and willing to give written .
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1

Study arms

  • Experimental
    Healthy Volunteers

    Drug: Baclofen · Drug: Memantine

  • Experimental
    Obese, Otherwise Healthy Volunteers

    Drug: Baclofen · Drug: Memantine · Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Safety and tolerability of co-administered baclofen and memantine via C-SSRS

    Time frame: From Baseline until Follow-up

  2. Safety and tolerability of co-administered baclofen and memantine via Adverse Events

    Time frame: From Baseline until Follow-up

  3. Safety and tolerability of co-administered baclofen and memantine via Vital Signs

    Time frame: From Baseline until Follow-up

  4. Safety and tolerability of co-administered baclofen and memantine via ECG

    Time frame: From Baseline until Follow-up

  5. Safety and tolerability of co-administered baclofen and memantine via Clinical Laboratory Tests

    Time frame: From Baseline until Follow-up

Secondary outcomes

  1. Pharmacokinetic parameters of co-administered baclofen and memantine via Cmax

    Time frame: From Baseline until Day 32

  2. Pharmacokinetic parameters of co-administered baclofen and memantine via Tmax

    Time frame: From Baseline until Day 32

  3. Pharmacokinetic parameters of co-administered baclofen and memantine via AUC

    Time frame: From Baseline until Day 32

  4. Pharmacokinetic parameters of co-administered baclofen and memantine via MRT

    Time frame: From Baseline until Day 32

  5. Pharmacokinetic parameters of co-administered baclofen and memantine via CL/F

    Time frame: From Baseline until Day 32

  6. Pharmacokinetic parameters of co-administered baclofen and memantine via T1/2

    Time frame: From Baseline until Day 32

  7. Pharmacokinetic parameters of co-administered baclofen and memantine via CLR

    Time frame: From Baseline until Day 32

07

Study locations

1 site
  • Quintiles Drug Research Unit at Guy's Hospital
    London, United Kingdom
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 8, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02001584
Lead sponsor
Gedeon Richter Plc.
Responsible party
Sponsor
First posted
Dec 5, 2013
Primary completion
May 2014
Completion
May 2014
Last update
Jul 8, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Baclofen · Memantine

Start the discussion